Document:

<PAGE>

                                                                EXHIBIT 10.17(B)

                               OPERATION AGREEMENT

This Agreement is entered into by and between the following parties:

(1)  Bridgetech Medical Technologies Research & Development Limited, a company
     whose registered office is at Unit 2401-02, 24/F Admiralty Centre II, 18
     Harcourt Road, Admiralty, Hong Kong SAR, China ("BMT R& D"); and

(2)  The Chinese University of Hong Kong at Shatin, New Territories, Hong Kong
     SAR ("CUHK").

Services to be performed by CUHK:   as detailed in Schedule A (the "SERVICES")

Obligations of BMT R&D:             as detailed in Schedule B

IN WITNESS WHEREOF, these duly authorized representatives of the parties hereby
execute this Agreement, including all the terms and conditions and schedules
which follow.

for and on behalf of
THE CHINESE UNIVERSITY OF HONG KONG

Signature: /s/ Ngan, Alice Man Wai
           --------------------------
Name: Ngan, Alice Man Wai (Ms)
Title: Director
       Research and Technology
       Administration Office
Date: May 24, 2006

for and on behalf of
BRIDGETECH MEDICAL TECHNOLOGIES
RESEARCH & DEVELOPMENT LIMITED

Signature: /s/ Thomas C. Kuhn III
           --------------------------
Name: Thomas C. Kuhn III
Title: Director
Date: May 15, 2006

                                                                     Page 1 of 7

<PAGE>

1.   ENGAGEMENT

1.1  BMT R&D hereby confirms the engagement of CUHK and CUHK hereby confirms its
     agreement to make available to BMT R&D the Services upon and subject to the
     terms set out in this Agreement.

1.2  The engagement of CUHK to provide the Services shall commence upon the
     signing of this Agreement and shall terminate in accordance with CLAUSE 8
     of this Agreement.

1.3  The Services under this Agreement shall be provided by CUHK in compliance
     with the prevailing standard of accepted business practices and ethics. The
     parties herein shall act in the best interests of each other at all times
     subject to the terms of this Agreement.

1.4  BMT R&D and CUHK acknowledge and agree that the Services under this
     Agreement shall not be provided to BMT R&D on an exclusive basis. This
     Agreement shall not be construed to limit CUHK's ability to perform
     services to third parties which are identical or similar to the Services.

2.   CUHK'S UNDERTAKINGS

     CUHK warrants and undertakes to BMT R&D that:

     (a)  CUHK will provide the Services in Schedule A;

     (b)  CUHK will provide advice to BMT R&D in relation to the Services; and

     (c)  the Services will conform to the standards generally observed in the
          industry for similar services.

3.   BMT R&D'S OBLIGATIONS

     BMT R&D shall be responsible for the performance of the obligations in
     Schedule B, and shall perform the said obligations in compliance with the
     standards, ethnical and otherwise, generally observed in the industry.

4.   ISSUANCE OF SHARES

     In consideration for the Services, BMT R&D shall as soon as practicable
     after the date of this Agreement issue and allot 8,166,667 fully paid-up
     shares of HK$1.00 each in BMT R&D, free from any encumbrances, to CUHK (or
     as CUHK may otherwise direct which, without limitation, may include the
     Chinese University of Hong Kong Foundation Limited) at no additional cost,
     levy or charge, which shall be equivalent to 49% of the issued capital in
     BMT R&D.

5.   INSURANCE, FEES AND EXPENSES

5.1  Subject to CLAUSES 5.2 and 5.3, CUHK shall bear all fees and expenses
     incurred by it in the performance of the Services as set out in Schedule A.
     BMT R&D shall not reimburse CUHK for any fees or expenses incurred by CUHK.

5.2  BMT R&D shall arrange for and maintain, at its cost, insurance policies
     (naming BMT R&D, CUHK and its shareholders as beneficiaries) covering
     general liability and errors and omissions in respect of BMT R&D , its
     employees, shareholders or contractors. Such insurance policies shall be on
     terms as agreed between the parties.

                                                                     Page 2 of 7

<PAGE>

5.3  BMT R&D and CUHK agree that:

     (a)  any secondment of personnel by any party, for part-time employment,
          consultancy or full-time employment, or any use of facilities or
          premises shall be on terms (including payment terms) to be agreed by
          BMT R&D and CUHK; and

     (b)  BMT R&D will pay CUHK or the relevant personnel of CUHK (in which case
          the written consent of CUHK must be obtained by the personnel) on
          terms to be agreed by the relevant parties for the following services:

          (i)  services of Prof. Benny Chung-Ying Zee;

          (ii) supply of personnel for the management of the day-to-day
               operations of BMT R& D;

          (iii) supply of personnel for other operations of BMT R&D;

          (iv) supervision of data collection and management of trials;

          (v)  introduction of third party projects to be performed on a fee for
               service basis;

          (vi) provide office space for additional personnel hired by BMT R&D;
               and

          (vii) services relating to existing computer resources and information
               technology equipment of the Centre for Clinical Trials of CUHK.

6.   INTELLECTUAL PROPERTY RIGHTS AND ROYALTIES

6.1  BMT R&D shall be entitled to all brands, trade marks, service marks, logos,
     inventions, property, copyright, designs, trade names, internet domain
     names, patents and other intellectual property rights ("BMT IPR") which are
     developed with resources provided by BMT R&D and BMT R&D shall be entitled
     to all rights (including royalties and payments by third parties) in
     relation thereto.

6.2  CUHK shall do all things and sign all documents or instruments reasonably
     necessary to enable BMT R&D to obtain, defend and enforce its rights in the
     BMT IPR. For the avoidance of doubt, to the extent that CUHK is the
     beneficial owner of such BMT IPR, CUHK hereby, as beneficial owner, assigns
     all such BMT IPR to BMT R&D and agrees to do all things and sign all
     documents or instruments reasonably necessary to perfect such assignment.

6.3  The provisions of this CLAUSE 6 shall survive the termination of this
     Agreement.

7.   ASSIGNMENT

     Either party shall not be entitled to assign any of its rights or
     obligations under this Agreement or to sell, transfer or otherwise dispose
     of the shares of BMT R&D without the prior written consent of the other
     party and in accordance with the Shareholders' Agreement dated on or around
     the date of this Agreement between the Chinese University of Hong Kong
     Foundation Limited, Bridgetech Holdings International, Inc. and BMT R&D as
     amended from time to time.

8.   TERMINATION

8.1  (a)  Without limiting the rights of the parties at law, either party shall
          be entitled to terminate this Agreement with immediate effect (and
          without any notice) if either party attempts to assign any of its
          rights or obligations under this Agreement or to sell, transfer or
          otherwise dispose of the shares of BMT R&D in breach of CLAUSE 7.

     (b)  Either party shall be entitled to terminate this Agreement after the
          third anniversary of this Agreement by serving 3 months' notice in
          writing to the other party.

                                                                     Page 3 of 7

<PAGE>

8.2  On the termination of this Agreement, all rights and obligations of the
     parties under this Agreement shall automatically terminate except for such
     rights of action as shall have accrued prior thereto and any obligations
     which expressly or by implication are intended to come into or continue in
     force on or after such termination. For the avoidance of doubt, the
     shareholders of BMT R&D shall not be required to sell, transfer or
     otherwise dispose of the shares of BMT R&D upon termination of this
     Agreement.

9.   GENERAL PROVISIONS

9.1  Any notices given under this Agreement will be in writing and delivered by
     mail, by hand, or by facsimile addressed to the parties as follows:

<TABLE>
<S>                                   <C>
CUHK                                  BMT R&D

The Chinese University of Hong Kong   Bridgetech Medical Technologies Research
                                      & Development Limited

Room 226, Pi Ch'iu Building           Unit 2401-02, 24/F Admiralty Centre II, 18 Harcourt
Shatin, New Territories               Road, Admiralty, Hong Kong SAR
Hong Kong SAR

Attn: Ms Alice Ngan                   Attn: Thomas C. Kuhn III
      Director                              Director
      Research and Technology
      Administration Office
Telephone: (852) 2609 8883            Telephone: (852) 2114 4994
Facsimile: (852) 2603 5451            Facsimile: (852) 2110 5780
</TABLE>

9.2  Any accommodation or indulgence or failure to enforce a right shall not be
     construed as a waiver of the right of any party exercisable under this
     Agreement unless a waiver shall be specifically stated in writing signed by
     such party.

9.3  This Agreement constitutes the entire understanding between the parties
     concerning the subject matter hereof. No amendments or changes shall be
     made to this Agreement unless agreed to in writing by the parties. Each
     provision of this Agreement shall be construed separately and
     notwithstanding that the whole or any part of any such provision may prove
     to be illegal or unenforceable the other provisions of this Agreement and
     the remainder of the provision in question shall continue in full force and
     effect.

9.4  Each party shall bear its own costs and expenses in connection with the
     preparation, negotiation and execution of this Agreement.

9.5  This Agreement shall be governed by and construed in accordance with the
     laws of Hong Kong and the parties hereby irrevocably submit to the
     non-exclusive jurisdiction of the Hong Kong courts.

                                                                     Page 4 of 7

<PAGE>

                                   SCHEDULE A

                                    SERVICES

CUHK shall:

(a)  facilitate access to experts for the conducting of clinical trials, whether
     within or outside of CUHK;

(b)  facilitate access to necessary resources of CUHK for the conducting of
     trials; and

(c)  facilitate access to an extensive network of collaborators in China.

                                                                     Page 5 of 7

<PAGE>

                                   SCHEDULE B

                                   OBLIGATIONS

BMT R&D shall:

(a)  ensure that the employees of BMT R&D shall co-operate fully with CUHK in
     relation to the provision of the Services;

(b)  promptly furnish CUHK with such information and documents as it may
     reasonably request for the proper performance of its obligations hereunder;

(c)  provide adequate funding to meet the estimated budget in Schedule C as
     nearly as possible for project management and data management services for
     multi-centre clinical trials;

(d)  establish an office in Hong Kong to meet the requirements with respect to
     staffing, equipment and office in Schedule C as nearly as possible;

(e)  register BMT R&D in China;

(f)  introduce trials to investigators of major clinical centres in Guangzhou,
     Beijing, Shanghai and other locations in the Peoples Republic of China as
     deemed necessary for regulatory approval;

(g)  use reasonable endeavours to introduce trials to investigators of other
     clinical centres in China; and

(h)  for matters of a medical or an ethical nature, comply with the ethical
     standard set forth by the Joint CUHK-NTEC Clinical Research Ethics
     Committee as amended from time to time and obtain the approval of such
     committee when necessary.

                                                                     Page 6 of 7

<PAGE>

                                   SCHEDULE C

            ESTIMATED OPERATION AND OFFICE RENTAL BUDGET FOR BMT R&D

<TABLE>
<CAPTION>
                                                        YEAR 1       YEAR 2       YEAR 3        TOTAL
                   OPERATION COST                       (HK $)       (HK $)       (HK $)        (HK $)
                   --------------                     ----------   ----------   ----------   -----------
<S>                                                   <C>          <C>          <C>          <C>
STAFF COST
Director                                                 600,000      600,000      600,000     1,800,000
Administrative and Accounting                            360,000      360,000      360,000     1,260,000
System Analyst                                           300,000      300,000      300,000       900,000
Database Programmer                                      300,000      300,000      300,000       900,000
Clinical Trials and Nursing Specialist                   420,000      420,000      420,000     1,080,000
MSc Statistician                                         300,000      300,000      300,000       900,000
Data Entry Clerks                                        144,000      144,000      144,000       432,000
                                                      ----------   ----------   ----------   -----------
      SUB-TOTAL (HKD)                                  2,424,000    2,424,000    2,424,000     7,272,000
                                                      ----------   ----------   ----------   -----------

EQUIPMENTS
Computer Servers                                         100,000                                 100,000
Central Storage System                                   200,000                                 200,000
Backup Server with Tape Auto Loader                      100,000                                 100,000
Printer and copy machine                                  60,000                                  60,000
Network                                                   25,000       25,000       25,000        75,000
Firewalls                                                100,000                                 100,000
Oracle tools and licenses                                100,000       20,000       20,000       140,000
Annual licenses for Operating System and Statistics       50,000       50,000       50,000       150,000
Laboratory equipments and reagents                       200,000       50,000       50,000       300,000
Fridge                                                    80,000                                  80,000
Freezer                                                  100,000                                 100,000
Equipments for potential centres in China                100,000      100,000      100,000       300,000
                                                      ----------   ----------   ----------   -----------
   SUB-TOTAL (HKD)                                     1,215,000      245,000      245,000     1,705,000
                                                      ----------   ----------   ----------   -----------
      TOTAL (NOT INCLUDING OFFICE RENTAL)              3,639,000    2,669,000    2,669,000     8,977,000
                                                      ==========   ==========   ==========   ===========
</TABLE>

<TABLE>
<CAPTION>
                                                        YEAR 1       YEAR 2       YEAR 3        TOTAL
                   OFFICE RENTAL                        (HK $)       (HK $)       (HK $)        (HK $)
                   -------------                      ----------   ----------   ----------   -----------
<S>                                                   <C>          <C>          <C>          <C>
4500 square feet office                                 783,000       783,000      783,000     2,349,000
Renovation                                              600,000                                  600,000
Maintenance                                             120,000       120,000      120,000       360,000
Insurance for human resources                           120,000       120,000      120,000       360,000
                                                      ----------   ---------    ----------   -----------
   SUB-TOTAL (HKD)                                     1,623,000    1,023,000    1,023,000     3,669,000
                                                      ----------   ----------   ----------   -----------
      TOTAL                                           $5,262,000   $3,692,000   $3,692,000   $12,646,000
                                                      ==========   ==========   ==========   ===========
</TABLE>

                                                                     Page 7 of 7<PAGE>

                                                                   EXHIBIT 10.22

                          STRATEGIC ALLIANCE AGREEMENT

     THIS STRATEGIC ALLIANCE AGREEMENT (this "AGREEMENT"), effective as of
October 19, 2005, is made by and between BRIDGETECH HOLDINGS INTERNATIONAL,
INC., a Delaware corporation ("BRIDGETECH"), and MCC Global Healthcare Group, a
Corporation ("MCCHG"), (MCCHG together with Bridgetech, the "PARTIES").

                                   WITNESSETH

     WHEREAS, MCCHG provides strategically driven excellence in business
development, financial, operational and globalization for client companies;

     WHEREAS, BRIDGETECH is leveraging its extensive relationships in China and
the U.S. to capitalize on proprietary opportunities in high growth segments of
the healthcare industry

     WHEREAS, the Parties wish to form a Strategic Alliance in order to leverage
geographical and market strengths for the introduction, regulatory approval, and
distribution of healthcare products and services globally;

     NOW THEREFORE, in consideration of the premises and of the mutual covenants
contained in this Agreement, and for other good and valuable consideration, the
receipt and adequacy of which is hereby acknowledged, the Parties agree as
follows.

     Definitions:

     ENTITY - a joint venture or other organizational structure as deemed
     appropriate by the Parties.

     PRODUCT - a drug, device or diagnostic.

     NET REVENUE - Gross Sales Revenue from a product, less direct cost of sales
     of that product and royalties established with third parties from whom the
     related Product was licensed.

1.   The Project.

     1.1  Each company will have a protected country or region where the
          proposed Strategic Alliance will not impact their current operations.
          Those will be as follows:

          (a)  BTHI - "Asia" - China, Hong Kong, Singapore, Philippines,
               Vietnam, Thailand, Laos, Burma, Indonesia, Australia, Korea,
               Taiwan, and Malaysia;

          (b)  MCC - "World" - Europe, USA, and South Africa.

     1.2  Each partner will create an Entity to pursue sales of Product in the
          other party's protected country or region. Opportunities may be
          introduced by one party and require the acceptance of the other party.
          All interests in these Entities will be shared 51% by the Entity Owner
          and 49% by the other partner.

     1.3  The two companies may create Entities in unprotected countries or
          regions for purposes of introducing Products. The Parties agree to use
          reasonable best efforts to establish a structure through which to
          handle these transactions.

2.   Assignment.

<PAGE>

     2.1  Bridgetech shall have the right to assign (with the written approval
          of MCCHG) this contract to one of its subsidiaries, or to an entity
          that Bridgetech creates, as needed to facilitate the distribution
          efforts in Asia;

3.   Term and Termination.

     3.1  Term. The Agreement will have an initial term of 10 years (the
          "PROJECT TERM"), at the end of which time the Project Term may be
          extended for additional 1 year terms (all such renewal terms shall be
          considered part of the "Project Term"), unless either Party notifies
          the other no later than 60 days before the end of the Project Term
          that it does not wish to extend the Project Term.

4.   Representations and Warranties.

     4.1  Representations and warranties of the Parties The Parties hereby
          represent and warrant as follows:

          (a)  Status. BRIDGETECH is a corporation validly existing and in good
               standing under the laws of the State of Delaware, U.S.A.
               BRIDGETECH has all necessary power to enter into this Agreement.

          (b)  Status. MCCHG is a Delaware corporation duly organized, validly
               existing and in good standing under the laws of Delaware. MCCHG
               has all necessary power to enter into this Agreement.

          (c)  Authorization, etc. The execution, delivery and performance by
               the Parties of this Agreement has been authorized by all
               necessary action on the part of such entity and its stockholders,
               as the case may be, and does not and will not

               (i)  violate the organizational documents of the Parties or any
                    applicable law, or

               (ii) contravene, conflict with, or result in a default under any
                    order or judgment of any court or other governmental
                    authority or any agreement to which the Parties may be
                    bound.

          (d)  Enforceability. Its obligations and the obligations of the
               Parties under this Agreement and any other agreement entered into
               by such entity in connection with this Agreement or the Project
               are and will be the legal, valid, and binding obligation of the
               Parties, enforceable against such entity in accordance with its
               terms, subject to applicable bankruptcy, reorganization,
               insolvency, moratorium, or similar laws affecting creditors'
               rights generally and subject as to enforceability, to equitable
               principle of general application regardless of whether
               enforcement is sought in a proceeding in equity or at law.

          (e)  Litigation. There are no suits, proceedings, judgments, rulings
               or orders by or before any governmental authority, court or
               arbitrator or any pending or threatened action or proceeding
               affecting the Parties before any governmental authority, court or
               arbitrator that could reasonably be expected to materially and
               adversely affect the financial condition or operations of the
               Parties or the ability of the Parties to perform their respective
               obligations under this Agreement or any other agreement entered
               into by such entity in connection with this Agreement or the
               Project, or which purports to affect the legality, validity or
               enforceability of this Agreement or any other such agreement.

                                        2

<PAGE>

5.   Confidential Information. For purposes of this Agreement "CONFIDENTIAL
     INFORMATION" means information provided by a Party to this Agreement (the
     "DISCLOSING PARTY") to any other Party to this Agreement (the "RESTRICTED
     PARTY") in connection with the transactions and relationships contemplated
     by the Project, including but not limited to:

          (a)  any data or information that is competitively sensitive material,
               and not generally known to the public, including, but not limited
               to, Product, planning information, marketing strategies, plans,
               finance operations, sales estimates, business plans, and internal
               performance results relating to the past, present or future
               business activities of the Disclosing Party and, services and
               Product provided to or obtained from, the terms of related
               contracts with, and the identities of any other identifying
               information regarding the customers, clients and suppliers of the
               Disclosing Party;

          (b)  any scientific or technical information, design, process,
               procedure, formula, or improvement that is commercially valuable
               and secret in the sense that its confidentiality affords the
               Disclosing Party a competitive advantage over its competitors;

          (c)  all confidential or proprietary concepts, documentation, reports,
               data (including magnetic tapes), specifications, web sites,
               screen formats, computer software, source code, object code, flow
               charts, databases, inventions, systems, system security features,
               system enhancements, information, know-how, show-how and trade
               secrets, whether or not patentable or copyrightable;

          (d)  all documents, inventions, substances, engineering and laboratory
               notebooks, drawings, diagrams, specifications, bills of material,
               equipment, prototypes and models, and any other tangible
               manifestation of the foregoing;

          (e)  any other information that a Disclosing Party treats as
               confidential information provided by an affiliate or other third
               party; and

          (f)  any information derived from any of the foregoing that is treated
               as confidential.

     Such Confidential Information shall not be disseminated or disclosed
     without prior consent by both Parties.

6.   Press Release and Announcements.

          The Parties agree that no public release or announcement concerning
     the transactions contemplated hereby shall be issued or made by or on
     behalf of any Party without the prior consent of the other Party, except
     that either Party may, after consultation with counsel, make announcements
     that such Party reasonably may determine are necessary to comply with
     applicable law. MCCHG acknowledges and agrees that BRIDGETECH may be
     required to announce the terms of this Agreement and make publicly
     available this Agreement and that no breach shall be deemed to result
     therefrom. Notwithstanding the foregoing, the Parties cooperate to prepare
     a joint press release to be issued in connection with the execution of this
     Agreement. The Parties further agree that each shall have the right to
     display the others logo on their respective websites.

                                        3

<PAGE>

                                   Section 1.

7.   Indemnification.

     7.1  Indemnification. Each Party (the "Indemnifying Party") will defend,
          indemnify, and hold the other Party, it officers and directors,
          shareholders, and each of its and their successors and permitted
          assigns (the "Indemnified Parties"), harmless from and against any and
          all liabilities, judgments, losses, actual damages, costs, and
          expenses (including without limitation reasonable attorneys' and
          experts' fees) which any or all of them may hereafter incur themselves
          or pay out to another by reason of any claim, suit, or proceeding
          brought by a third party, at law or in equity, that arises out of or
          relates to (i) a material breach of any representation, warranty,
          covenant, obligation or other provision of this Agreement by the
          Indemnifying Party or (ii) any other Event of Default, except to the
          extent caused by the gross negligence or willful misconduct of an
          Indemnified Party.

     7.2  Exclusion of Consequential Damages. NOTWITHSTANDING ANYTHING TO THE
          CONTRARY CONTAINED IN THIS AGREEMENT, NEITHER PARTY SHALL, UNDER ANY
          CIRCUMSTANCES, BE LIABLE TO THE OTHER PARTY FOR LOST PROFITS,
          CONSEQUENTIAL, INCIDENTAL, SPECIAL, PUNITIVE, OR INDIRECT DAMAGES
          ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS
          CONTEMPLATED HEREUNDER, EVEN IF THE PARTY HAS BEEN APPRISED OF THE
          LIKELIHOOD OF SUCH DAMAGES.

8.   Miscellaneous.

     8.1  Binding Effect. This Agreement shall be binding on and inure to the
          benefit of the Parties and their respective successors and permitted
          assigns.

     8.2  Assignment. This Agreement, except for as outlined in Section 2.1,
          shall not be assigned by either Party without the prior written
          consent of the other Party, not to be unreasonably delayed or
          withheld, and any purported such assignment without such consent shall
          be void. For purposes of this Section 8.2, a merger involving a Party
          shall be deemed to result in an assignment of this Agreement to the
          surviving entity in the merger, regardless of whether the Party is the
          surviving entity or merging entity to such merger.

     8.3  Notices and Other Communications.

          (a)  Each notice, communication and delivery under this Agreement (i)
               shall be made in writing signed by the Party making the same,
               (ii) shall specify the Section of this Agreement pursuant to
               which it is given, (iii) shall be given either in person or by
               telecopier, effective upon such delivery or the confirmed
               transmission and (iv) if not given in person, shall be sent to
               the applicable Party at the address set forth below (or at such
               other address as the applicable Party may furnish to the other
               Party pursuant to this subsection) by international courier
               delivery service, effective upon the second business day after
               such notice is deposited, delivery charges pre-paid, with such
               international courier delivery service. Each Party's notice
               information is as follows:

                                        4

<PAGE>

     BRIDGETECH: Bridgetech Holdings International, Inc.
                 777 S. Highway 101, Suite 215
                 Solana Beach, California 92075
                 Attn: Thomas C. Kuhn III
                 Phone: 619-342-7440
                 Fax: 619-342-7497

                 With a copy to:

                 Sutherland Asbill & Brennan LLP
                 999 Peachtree Street, NE
                 Atlanta, Georgia 30309
                 Attn: B. Knox Dobbins
                 Phone: 404-853-8053
                 Fax: 404-853-8806

     MCCHG:      MCC Healthcare Group
                 12813 Travers Trail
                 Ft. Worth, Texas 76248
                 Attn: Paul L. Rudisill
                 Phone: 801-898-1027
                 Fax: 817-887-2577

                 With a copy to:

                 Salt Lake City
                 11585 South State Street, Suite 102
                 Draper, Utah 84020
                 Phone: 801-816-2500
                 Fax: 801-816-2599

                 Attn: Kenneth Denos

     8.4  Severability. If any term or provision of this Agreement, or the
          application thereof to any person or circumstance, shall to any extent
          be contrary to any applicable law or regulation or otherwise invalid
          or unenforceable, the remainder of this Agreement or the application
          of such term or provision to persons or circumstances other than those
          as to which it is contrary, invalid or unenforceable shall not be
          affected thereby and, to the extent consistent with the overall intent
          of this Agreement taken as a whole, shall be enforced to the fullest
          extent permitted by applicable law and regulation.

     8.5  Governing Law. The Project Documents will be governed by the laws of
          Delaware except as specifically provided in such documents, without
          regard to principles of conflict of laws.

                                        5

<PAGE>

9.   Warrants.

     9.1  BTHI shall grant to MCCHG warrants to purchase shares of common stock
          in the future in the following schedule:

          A:   $1,500,000 @ $2.50 per share, expiring nine (9) months from the
               effective date of this agreement. If at any time during the term
               of these warrants, the closing market price of BTHI's common
               stock equals or exceeds $5.00, for five consecutive business
               days, then these warrants will immediately become due. In this
               instance, MCCHG will have 10 business days to exercise the
               warrants or they shall expire.

          B:   $1,000,000 @ $4.00 per share, expiring fifteen (15) months from
               the effective date of this agreement. If at any time during the
               term of these warrants, the closing market price of BTHI's common
               stock equals or exceeds $8.00, for five consecutive business
               days, then these warrants will immediately become due. In this
               instance, MCCHG will have 10 business days to exercise the
               warrants or they shall expire.

10.  Services.

     10.1 BTHI shall agree to work with MCCHG on the following areas:

          A:   BTHI will review MCCHG service offerings and select those that
               BTHI deems necessary to engage. Success fees will be paid on
               these selected services as agreed to under separate agreements
               between both parties.

          B:   BTHI agrees to consider moving to a listing on the AIM market. In
               the event that the AIM listing is pursued by BTHI, MCC's
               Securities will be the financial advisor. In the event other
               forms of capital is sought i.e. private, institutional, etc.
               MCC's Securities will be given the right to propose for such
               representation.

IN WITNESS WHEREOF, the Parties have executed this Agreement, or caused it to be
executed by their duly authorized officers or agents all as of the day and year
first above written.

                                        BRIDGETECH HOLDINGS INTERNATIONAL, INC.

                                        By: /s/ Thomas C. Kuhn III
                                            ------------------------------------
                                        Name: Thomas C. Kuhn III
                                        Title: EVP & CFO

                                        MCC HEALTHCARE GROUP

                                        By: /s/ Paul L. Rudisill
                                            ------------------------------------
                                        Name: Paul L. Rudisill
                                        Title: CEO

                                        6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00106-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00106-of-00352.parquet"}]]